Skip to main content

Table 1 Summary of dose level and dose-limiting toxicities in phase 1

From: Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response

Patient no. Dose level Dose-limiting toxicities
001 1 nil
002 1 nil
003 1 nil
004 2 nil
005 2 nil
006 2 nil
007 3 nil
008 3 Grade 3 syncope
009 3 nil
010 3 nil
011 3 nil
012 3 Treatment delay for > 2 weeks due to prolonged neutropenia
013 2 nil
014 2 nil
015 2 nil
016 2 nil
017 2 nil
018 2 nil
019 2 nil